HAS opinions and decisions
La fiche de bon usage du médicament intitulée « Xolair (omalizumab) dans le traitement de l’asthme sévère», ci-jointe, est adoptée.
See also
HAS opinions and decisions
17/11/2017
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
6TW0R3qxtBGEJZ3U